# Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

> **NCT00171418** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 54 (—)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** Tegaserod

## Key facts

- **NCT ID:** NCT00171418
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 54 (—)
- **Last updated:** 2008-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171418, "Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00171418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*